Metabolic & Bariatric Surgery

EDITORIAL

By Philip Schauer, MD

The GLP-1 revolution has transformed the treatment landscape for obesity. As increasingly effective pharmacologic agents become available, the number of patients pursuing bariatric surgery has declined. This shift raises an important question: Should enthusiasm for GLP-1 therapy diminish the role of metabolic and bariatric surgery? The answer is a resounding no.

For patients with moderate to severe obesity, bariatric surgery remains the most effective treatment ever developed. Multiple meta-analyses continue to demonstrate that surgery produces substantially greater weight loss than GLP-1-based therapy, with differences approaching 20% of total body weight in favor of surgery. More importantly, these advantages persist over time, reinforcing the unmatched durability of surgical treatment. Unlike pharmacotherapy, which often requires lifelong administration and may be associated with weight regain after discontinuation (up to 50% at one year), bariatric surgery alters the physiology of obesity in a more enduring manner.

The superiority of surgery extends well beyond weight reduction. Bariatric procedures consistently produce profound improvements in obesity-related comorbidities, including type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, and metabolic dysfunction-associated steatotic liver disease. Rates of diabetes remission are particularly impressive and frequently exceed those observed with medical therapy alone. As these conditions improve, patients often experience substantial reductions in costly medication requirements, decreasing dependence on multiple chronic therapies.

Perhaps most compelling is the extensive evidence demonstrating reductions in long-term mortality after bariatric surgery. Decades of observational studies have shown decreases in deaths related to cardiovascular disease, cancer, and diabetes. Few interventions in modern medicine can claim such broad and durable survival benefits.

Safety concerns surrounding bariatric surgery often reflect outdated perceptions. Contemporary metabolic surgery has an excellent long-term safety profile, with complication rates comparable to those of many commonly performed abdominal procedures. Importantly, bariatric surgery has been studied extensively for more than 40 years. Its benefits, limitations, and long-term sequelae are well characterized.

GLP-1 agents unquestionably represent a major therapeutic advance and will continue to expand treatment options for obesity. Yet many important questions remain regarding their very long-term safety, the consequences of decades of continuous use, and the economic implications of lifelong therapy. Emerging evidence also suggests that surgery may offer lower long-term costs than chronic GLP-1 treatment.

The future of obesity care should not be framed as a competition between surgery and pharmacotherapy. However, in the current era of enthusiasm surrounding GLP-1 agents, it is essential to remember that bariatric surgery remains the benchmark against which all other obesity treatments should be measured.

Disclosures. Dr. Schauer’s financial and professional relationships are listed in the MBS Digest Disclosure Registry. Entries are self-reported and shown as submitted. The views expressed in this editorial are the author’s own and do not necessarily represent the position of the MBS Digest Editorial Board.

Production Editor: John D. Scott, MD, FACS | [email protected]

We welcome inquiries, tips, letters to the editor, and article ideas from the MBS community. Reach us at [email protected].

The MBS Digest | For Educational Purposes Only | Not for Redistribution